The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Oxidative Stress in Schizophrenia
Open accessAbstract
Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive, specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free Radicals in Biology and Medicine
Halliwell, B., & Gutteridge, J. M. C. (2015) · doi:10.1093/acprof:oso/9780198717478.001.0001 · Cited by 8,990
Uttara, B., Singh, A., Zamboni, P., & Mahajan, R. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602823 · Cited by 3,378 · cited 1×
“Of all the brain regions, the basal ganglia may be at particular risk for RS induced damage due to their large content of iron [7, 14-16].”
BackgroundOxidative stress and neurodegeneration: where are we now?
Halliwell, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03907.x · Cited by 2,614
Halliwell, B., & Whiteman, M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705776 · Cited by 2,238
Halliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
4-Hydroxy-2-nonenal: a product and mediator of oxidative stress
Uchida, K. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00014-6 · Cited by 1,164
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069 · cited 1×
“Oxidative stress is common to several psychiatric disorders [5].”
BackgroundCatecholamine metabolism: basic aspects and clinical significance.
Kopin, I. J. (1985) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06859-0 · Cited by 582
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo
Do, K. Q., Trabesinger, A. H., Kirsten‐Krüger, M., Lauer, C. J., Dydak, U., Hell, D., Holsboer, F., Boesiger, P., & Cuénod, M. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00229.x · Cited by 540 · cited 3×
“It has been reported that GSH levels are decreased by 27% in the cerebrospinal fluid and 52% in prefrontal complex of drug-naive patients with schizophrenia [25].”
BackgroundN -acetylcysteine for antioxidant therapy: pharmacology and clinical utility
Dodd, S., Dean, O., Copolov, D. L., Malhi, G. S., & Berk, M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14728220802517901 · Cited by 413
Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371
Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00083-9 · Cited by 329 · cited 1×
“Meta-analysis of 5 eligible studies reported in Table 3 [148-152] revealed insignificant improvement on PANSS score (WMD 2.”
MethodAltered glutathione redox state in schizophrenia.
Yao, J. K., Leonard, S., & Reddy, R. (2006) · Disease Markers · doi:10.1155/2006/248387 · Cited by 321
Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder
Kuloglu, M., Ustundag, B., Atmaca, M., Canatan, H., Tezcan, A. E., & Cinkilinc, N. (2002) · Cell Biochemistry and Function · doi:10.1002/cbf.940 · Cited by 321 · cited 1×
“While the majority of studies have reported decreased antioxidant defense in patients with schizophrenia [4, 10, 13, 21, 26, 42-54] there are also some studies where the opposite has been reported [12, 55-59].”
Dakhale, G. N., Khanzode, S. D., Khanzode, S. S., & Saoji, A. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0117-1 · Cited by 131 · cited 1×
“Available studies with vitamin C treatment and treatment with combinations of vitamin C and vitamin E show a significant improvement in BPRS score and reduction in dyskinetic movement total score [117, 146].”
BackgroundSivrioglu, E. Y., Kirli, S., Sipahioglu, D., Gursoy, B., & Sarandöl, E. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.004 · Cited by 102
Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia
Bulut, M., Savas, H. A., Altindag, A., Virit, O., & Dalkilic, A. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970903144004 · Cited by 73 · cited 2×
“In addition, supplementation with other antioxidants such as N-Acetyl Cysteine [118-121], rutin [122], Ginkgo biloba [54, 123-126], melatonin [127-129], hydroxytyrosol [130], caffeic acid phenethyl ester [131], resveratrol and quercetin [132] and lycopene [133, 134] has been suggested.”
BackgroundMethod
Cited by
Role of oxidative stress in depression
Bhatt, S., Nagappa, A. N., & Patil, C. R. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.05.001 · Cited by 821
Endogenous non-enzymatic antioxidants in the human body
Mirończuk-Chodakowska, I., Witkowska, A. M., & Zujko, M. E. (2018) · Advances in Medical Sciences · doi:10.1016/j.advms.2017.05.005 · Cited by 613
Oxidative Stress and Psychological Disorders
Salim, S. (2014) · Current Neuropharmacology · doi:10.2174/1570159x11666131120230309 · Cited by 557
Mitochondrial dysfunction in schizophrenia: Pathways, mechanisms and implications
Rajasekaran, A., Venkatasubramanian, G., Berk, M., & Debnath, M. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.11.005 · Cited by 279
Antioxidants as potential therapeutics for neuropsychiatric disorders
Pandya, C. D., Howell, K. R., & Pillai, A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.017 · Cited by 222
Metadata
- Authors
- Grabnar, I., Vovk, T., Kores Plesnicar, B., & Boskovic, M.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-06-01
- Volume
- 9
- Issue
- 2
- Pages
- 301-312
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2063361808
- Cited by
- 250
- References
- 18
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.